Lates News

On July 31st, Guoyao Group's Animal Health Co., Ltd. (hereinafter referred to as "Guoyao Animal Health") received good news: the company was granted the clinical trial approval for the African swine fever vaccine by the Ministry of Agriculture and Rural Affairs, becoming the first enterprise in China to receive this approval. Guoyao Animal Health has always closely monitored the trends of animal diseases at home and abroad, focusing on the research and development of vaccines for diseases such as porcine blue ear disease and porcine circovirus disease, and has previously developed the world's first gene-recombinant strain of porcine blue ear disease live vaccine. In 2021, the company boldly ventured into scientific "no man's land" and established a research and development team for the African swine fever vaccine. Over the past four years, the team has completed multiple research projects on antigen production technology, pilot process research, establishment of semi-finished and finished product testing methods, vaccine stability research, and other scientific research tasks to complete laboratory trials of multiple batches of African swine fever vaccines and research on the safety of the vaccine products (Hubei Daily).